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Background: Differences in genetics and receptor expression (phenotypes) of invasive ductal breast cancer (IDC) impact on
prognosis and treatment response. Immunohistochemistry (IHC), the most used technique for IDC phenotyping, has some
limitations including its invasiveness. We explored the possibility of contrast-enhanced positron emission tomography magnetic
resonance (CE-FDG PET/MR) to discriminate IDC phenotypes.
Methods: 21 IDC patients with IHC assessment of oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth
factor-2 (HER2), and antigen Ki-67 (Ki67) underwent CE-FDG PET/MR. Magnetic resonance-perfusion biomarkers, apparent
diffusion coefficient (ADC), and standard uptake value (SUV) were compared with IHC markers and phenotypes, using a Student’s
t-test and one-way ANOVA.
Results: ER/PR tumours demonstrated higher Kepmean and SUVmax than ER or PRþ tumours. HER2 tumours displayed higher
ADCmean, Kepmean, and SUVmax than HER2þ tumours. Only ADCmean discriminated Ki67p14% tumours (lower ADCmean) from
Ki67414% tumours. PET/MR biomarkers correlated with IHC phenotype in 13 out of 21 patients (62%; P¼ 0.001).
Conclusions: Positron emission tomography magnetic resonance might non-invasively help discriminate IDC phenotypes, helping
to optimise individual therapy options.
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The mainstay of breast cancer treatment remains surgical
resection, but the addition of systemic chemotherapy can reduce
the risk of relapse (Santa-Maria et al, 2015). Neoadjuvant
chemotherapy has been shown to have equivalent rates of
disease-free survival (DFS) and overall survival (OS) when
compared to adjuvant chemotherapy (Mauri et al, 2005). The
benefit to neoadjuvant chemotherapy is the increased rate of
breast-conserving surgery (Makris et al, 1998; Rastogi et al, 2008).
The adjuvant breast and bowel project has shown that patients
receiving neoadjuvant chemotherapy who had a complete
pathologic response have a significantly improved DFS and OS.
In the adjuvant breast and bowel project, the percentage of patients
with a complete pathologic response was as much as 26%
depending on the chemotherapy regimen (Rastogi et al, 2008),
and according to a meta-analysis, rates of complete pathologic
response ranged from 4 to 29% (Mauri et al, 2005). However, as
many as 21% of patients in the adjuvant breast and bowel project
had no clinical response (Rastogi et al, 2008).
It is also known that rates of response to neoadjuvant
chemotherapy depend significantly on the biomarker profiles of
the primary breast cancer (Precht et al, 2010; Esserman et al, 2012).
Therefore, the ability to reliably identify the biomarker profile
(phenotype) within the breast cancer may allow better selection of
patients for neoadjuvant chemotherapy and selection of indivi-
dualised therapy regimens, building the pillars for personalised
medicine. For example, luminal A tumours have been shown to be
less chemosensitive than other phenotypes of breast cancer, with
some studies showing that adjuvant chemotherapy did not provide
survival benefit for patients (Prat et al, 2015). Some studies have
suggested that patients with luminal A breast cancer when treated
with paclitaxel benefit only if the proliferation index is low. In
addition, in patients with HER2þ tumours, treatment with
trastuzumab has shown to be beneficial with increases in complete
response and event-free survival (Prat et al, 2015). These are just a
few examples of how regimens targeted at tumour phenotype have
proven beneficial.
This is particularly relevant in breast cancer due to its high level
of heterogeneity (Shipitsin et al, 2007; Almendro and Fuster, 2011).
Core biopsies are currently used to investigate cancer biomarkers,
but only a small portion of the tumour can be sampled, which is
not necessarily the predominant nor the most aggressive area,
raising the possibility of under-estimating the most aggressive
phenotype of cancer (Marusyk and Polyak, 2010). The sampling
error of core biopsies can lead to treating patients who may not
benefit from neoadjuvant chemotherapy or administering a
chemotherapy regimen that is not tailored to the patient.
In this study, we explored the ability of contrast-enhanced
breast [18F] FDG positron emission tomography magnetic
resonance (PET/MR) to identify the phenotype of breast cancer.
MATERIALS AND METHODS
Patient enrolment. This Health Insurance Portability and
Accountability Act compliant retrospective study was approved
by the institutional review board. Patients gave written informed
consent for study enrolment, including the possibility of using their
imaging, genetics, and clinical data in future evaluations.
The authors had full control of the data and information
submitted for publication and did not receive any financial support
for this research study.
Inclusion criteria: (a) recent diagnosis of invasive ductal
carcinoma, (b) biopsy of the primary breast cancer with available
biomarkers, (c) absence of treatment, (d) age older than 18 years,
(e) whole-body contrast-enhanced 18F FDG PET/MR that
included breast MR perfusion, (f) breast cancer diameter of at
least 20mm, and (g) whole-body staging follow-up of X12
months. We decided to choose a very conservative minimum size
criterion, a tumour diameter of at least 20mm, 5 times as thick as
our DWI sequence, to improve the robustness of ADC measure-
ments, to reduce the risk of averaging areas of possible geometric
distortion, and to reduce the risk of partial volume effect being 10
times as big as the PET voxel size.
Exclusion criteria included: (a) pregnancy; (b) blood glucose
levels 4140mg dl 1 (7.77mmol l 1); (c) inadequate PET/MR
images; (d) contraindication to MR imaging; and (e) inability to
tolerate being in the PET/MR imager.
Pathology. Core needle biopsies were performed under ultra-
sound guidance by a radiologist with more than 15 years of
experience (OAC). A pathology technologist fixed them in 10%
neutral buffered formalin (NBF) at the time of biopsy. All patients
who underwent mastectomy after completion of neoadjuvant
chemotherapy had the mastectomy specimens sent to the
department of pathology immediately after resection. They were
cut in 5mm thick slices and fixed in NBF for 6–48 h. Haematoxylin
and eosin and immunohistochemistry (IHC) studies were
evaluated by one pathologist (ML) with more than 12 years of
experience in breast pathology. Staining for oestrogen receptor
(ER), progesterone receptor (PR), and human epidermal growth
factor-2 (HER2) was performed as per AAP guidelines (Wolff et al,
2007; Hammond et al, 2010).
The Benchmark Ultra staining module (Ventana Medical
Systems Inc, Tucson, AZ, USA) was employed for IHC assessment
of ER, PR, and HER2. Paraffin fixed specimens were placed on
positively charged slides after being cut into 5mm-thick slices. For
assessment of ER and PR, slices were incubated at 70 1C for 2 h; for
HER2 assessment they were air-dried overnight at room
temperature. The following primary monoclonal antibodies
(Ventana Medical Systems Inc) were used: for ER, CONFIRM
anti-ER (SP1, 1 mgml 1); for PR, CONFIRM anti-PR (1E2,
1 mgml 1); and for HER2, PATHWAY anti-HER2/neu (4B5,
6 mgml 1). The pre-diluted monoclonal Clone 30-9 (Ventana
Medical Systems Inc) was used for assessment of antigen Ki-67
(Ki-67) expression, and a count of more than 500 neoplastic cells
was employed to measure the fraction of proliferating cells (KI-67
positive).
PET/MR protocol. All patients fasted for at least 6 h before
imaging. Blood glucose levels were assessed with a blood
glucometer (OneTouch Vita; LifeScan, Milpitas, CA, USA) before
imaging to ensure it was o140mg dl 1 (7.77mmol l 1).
Positron emission tomography magnetic resonance imaging
began 85±24min after FDG injection (mean dose, 4.44MBq per
kilogram of body weight, range, 370–400MBq). This incubation
time is explained by the legal and IRB mandatory requirement of
obtaining a standard of care PET-CT 60min after FDG injection
before acquiring any PET-MR. However, the reconstruction
software automatically corrects for the delay between the time of
FDG injection and that of PET data acquisition for each bed
position.
Positron emission tomography magnetic resonance studies were
acquired with a Biograph mMR imager (Siemens Healthcare).
They included a whole-body PET/MR acquisition and a dedicated
breast MR perfusion protocol. The whole-body PET/MR was
performed with a 16-channel head and neck surface coil and three
or four 12-channel body coils (depending on patient height)
combined to form a multichannel whole-body coil by using total
imaging matrix technology. Positron emission tomography mag-
netic resonance was acquired with the patient supine, from the
mid-thigh towards the head. Positron emission tomography data
were automatically attenuation corrected with attenuation maps
generated from the two-point Dixon sequence. This portion of the
exam was used only for measuring the SUVmax of the primary
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breast cancer; therefore, in Table 1 we provide only the pertinent
parameters. After this acquisition, the patient was placed prone,
and the dedicated breast study, including DWI and MR perfusion,
was acquired with a dedicated four-channel breast coil. The
scanner automatically generated both the ADC maps and the
subtracted post-contrast images at each time point. The pertinent
parameters are outlined in Table 1.
Image analysis. Images were analysed in consensus, by a nuclear
medicine physician (AS) with 33 years of experience and by a
radiologist with 17 years of experience in MR, on a dedicated
workstation (SyngoVia, Siemens Healthcare). The automated PET
encircling function from the mMR-general layout workflow was
used to include the entire FDG avid tumour and obtain the
SUVmax. For measuring the ADCmean, the same layout workflow
was used; the entire tumour was manually encircled on the DWI
and ADC images. Spatial correlation with subtracted MR perfusion
images was employed to improve lesion identification, when
necessary. For the MR perfusion analysis, a Tofts-based commer-
cially available software (Tissue4D, Siemens Healthcare) was
employed. The entire tumour was manually encircled on the earliest
contrast-enhanced subtracted image set that best demonstrated the
cancer against the adjacent normal tissues. Then, the following
measurements were obtained: mean volume transfer coefficient
(Ktrans), mean flux rate constant (Kep), mean extracellular volume
ratio (Ve), and the initial area under the curve (iAUC).
Statistical analysis. The possible association between PET-MR
biomarkers (ADCmean, Ktransmean, Kepmean, Vemean, iAUC, and
SUVmax) and IHC expression of ER, PR, HER2, and Ki67 was
assessed using two-sample Student’s t-tests, with a 0.05 significance
level. We matched our PET/MR biomarkers against IHC
expression of ER, PR, HER2, and Ki-67 on the biopsies from all
patients. The biomarkers were also matched against a cohort that
included the expression of the markers in the entire tumour in
those with residual cancer at mastectomy plus the biopsy in those
with a pathologic complete response at mastectomy.
The utility of biomarkers for predicting tumour phenotype was
assessed by one-way ANOVA. Tumour phenotype prediction
models were fit using linear discriminant analysis with leave-one-
out cross-validation. The statistical significance of fitted models
was assessed by permutation analysis. Two analyses were
performed. First, we predicted biopsy phenotype for all patients.
We also fit a second model, using full-tumour data when
available, and biopsy data for patients who did not have
detectable residual cancer. The statistical significance of the
number of correct predictions was determined by simulation,
conditional on the observed frequencies of subtypes in the data.
Data were analysed using R (Version 3.1.0; R Development Core
Team, 2014), with the MASS library extension (Venables et al,
2002).
RESULTS
We recruited 49 consecutive newly diagnosed non-operated
patients with IDC (all women, age 18–79) between March 2012
and February 2013. Twenty-eight of these were excluded for
the following reasons: 19 for non-availability of histology
biomarkers and 9 for having a cancer o20mm in maximal
diameter. Therefore, our final population consisted of 21
patients. They underwent neoadjuvant chemotherapy that con-
sisted of 5-Fluorouracil, epirubicin, and cyclophosphamide (FEC)
in 16, FEC plus paclitaxel in 3, and paclitaxel in 2.
For all these 21 patients, core biopsy specimens were available.
Entire tumour specimens from mastectomy were available for
16/21 patients; due to complete response to neoadjuvant
chemotherapy in 5/21, no residual tumour was available. ER, PR,
HER2, and Ki67 were assessed for 21/21 patients on biopsy
specimens, and on 16/21 on the whole excised tumour.
On biopsy specimens, we found 14/21 ERþ , 12/21 PRþ , 10/21
HER2þ , and 12/21 Ki-67 p14% patients (Table 2). This resulted
in 3/21 patients with a luminal A phenotype, 8/21 with a luminal B
phenotype, 3/21 with a luminal HER2 phenotype, and 7/21 with a
HER2 enriched phenotype (Table 2).
On whole-tumour assessment in the 16/21 patients with residual
tumour after neoadjuvant chemotherapy, we found: 11/16 ERþ ,
9/16 PRþ , 6/16 HER2þ , and 10/16 Ki67 p14% tumours
(Table 2). Three of these 16 patients were Ki67414% on biopsy
but Ki67 p14% on whole-tumour evaluation. In summary, upon
entire residual tumour evaluation 5/16 patients had a luminal A
Table 1. Technical details of the examination
MR
Plane
Area
scanned
iPat
TR
(ms)
TE
(ms)
Matrix NEX
FOV
(mm)
Thickness
(mm)
Gap
(mm)
FA
(degrees)
Voxel size
(mm)
Fat Sat
Whole-body
T1w 2-Point
Dixon VIBE
(for attenuation
correction only)
Coronal Whole
body
2 3.6 1st TE
1.225
2nd TE
2.45
79192 1 500 3.1 0 100 4.1 2.63.1 None
Breast DWI Axial Breast 2 9600 74 78192 3 340 4 0.8 1.81.8 4 Strong
Breast VIBE
(MR perfusion)
Axial Breast 2 5.3 1.7 130192 6 356 380 3.6 0 2, 5, 8, 12,
15, 20
2.3 1.73.6 None
PET
BP
Acquisition time/BP
(min)
Iterative reconstruction
algorithm
Iterations Subsets
FOV axial
(mm)
Voxel size
(mm3)
Image
grid
5–
6
4 AW OSEM 3D 3 21 258 2.02.02.0 172 172
Abbreviations: AW OSEM 3D¼ 3-dimensional attenuation weighted ordered subsets expectation maximisation iterative reconstruction algorithm; BP¼bed position; DWI¼diffusion weighted
imaging; FA¼ flip angle; FOV¼ field of view; FS¼ fat saturated; GE¼gradient echo; iPat¼ integrated parallel acquisition technique; MR¼magnetic resonance; PET¼positron emission
tomography; SPAIR¼ spectral adiabatic inversion recovery; TE¼ time of echo; TI¼ time of inversion; TR¼ time of repetition; VIBE¼ volume interpolated breath hold T1 weighted. For the
whole-body PET/MR, PET data underwent automatic attenuation correction using attenuation maps generated from the 2-point Dixon sequence. Whole-PET/MR pertinent technical details are
given in the above table.
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phenotype, 5/16 a luminal B phenotype, 1/16 a luminal HER2
phenotype, and 5/16 a HER2 enriched phenotype.
Combining the IHC of residual cancer at mastectomy in 16
cases and that obtained on biopsy in the 5 cases who had complete
response, we got these final results: 6/21 luminal A, 5/21 luminal B,
3/21 luminal Her2, and 7/21 Her2 enriched (Table 2).
Patients generally had high-grade tumours with 0/21 grade 1,
14/21 grade 2, and 7/21 grade 3. Based on biopsy and on entire
tumour plus biopsy, for those with complete regression, the same
results were obtained when evaluating for expression of ER, PR,
and HER2. Both the mean flux rate constant (Kepmean) and
maximum standard uptake value (SUVmax) differentiated
ER/PR and ER or PRþ tumours (Figures 1–3). Statistically
significant higher values of Kepmean (P¼ 0.011) and SUVmax
(P¼ 0.005) were found in ER/PR tumours as compared to
ER/PRþ tumours. No other imaging biomarkers were signifi-
cantly different (Table 3).
Statistically significant higher values of ADCmean (P¼ 0.009),
Kepmean (P¼ 0.028), and SUVmax (P¼ 0.046) were measured in
HER2 negative compared to HER2-positive tumours (Figure 2 and
Table 3).
As far as Ki67 expression, ADCmean values were statistically
significantly lower in Ki67p14% compared to Ki67414%
expression (P¼ 0.025 on biopsy, P¼ 0.011 on entire cancer plus
biopsy; Table 3 and Figure 3). No other PET-MR biomarkers
behaved differently in relation to Ki67 expression.
No grading differences were encountered between core biopsy
and whole-cancer specimens. Grade 2 breast cancers had lower
Kepmean (P¼ 0.036) and lower SUVmax (P¼ 0.042) than grade 3
tumours (Table 3). However, since there were no grade 1 tumours
in our patients, we could not evaluate the differentiation of all
grades.
No other imaging biomarkers showed a statistically significant
correlation with breast cancer biomarkers. Specifically, the transfer
constant (Ktransmean) was not significantly different for any of the
tested molecular expressions.
Upon multivariate analysis utilising Kepmean, ADCmean, and
SUVmax, we were able to correctly identify the tumour pheno-
type in 14/21 biopsies (67%; P¼ 0.001). However, upon cross-
validation, PET-MR biomarkers correctly predicted 8/21 phenotypes
(38%), and this was not statistically significant (P¼ 0.22;
Table 4).
When we explored the capability of the PET-MR biomarkers
against the phenotypes obtained from entire cancer specimens
from 16 patients plus biopsies from the 5 cases who experienced
complete remission, our model was capable of predicting the
correct phenotype in 13 out of 21 patients (62%; P¼ 0.001), and
when we cross-validated these results, the model correctly
predicted 10 out of 21 cases (48%). These results had statistical
significance (P¼ 0.04; Table 4).
DISCUSSION
Utilising a multivariate analysis with (a) SUVmax, (b) ADCmean,
and (c) Kepmean, we were able to correctly predict the phenotypes
of breast cancer in 14/21 cases (67%) compared to biopsy and
13/21 (62%) compared to excision of the whole tumour plus biopsy
in the five cases without residual disease at mastectomy. While
numerous previous studies have looked at the correlations of PET
and MR biomarkers with tumour genotypes and phenotypes, to
our knowledge, this is the first study that attempts to predict
tumour phenotype based on a multivariate analysis of both PET
and MR biomarkers. This could be useful for future patient
treatment or help patient selection for neoadjuvant therapy trials
since selected therapy is often based on hormone receptor status,
HER-2 status, and proliferation rate (Prat et al, 2015).
There was a statistically significant direct correlation of
ADCmean with HER2-positive tumours (P¼ 0.009), which is in
agreement with several previous papers (Martincich et al, 2012;
Choi et al, 2012a; Richard et al, 2013; Park et al, 2015; Lee et al,
2016). In our population, we found a direct correlation between
ADCmean and Ki-67p14% on biopsy (P¼ 0.025) and excision plus
biopsy (P¼ 0.011). However, published data on ADC and Ki-67
expression in breast cancer are conflicting (Jeh et al, 2011; Choi
et al, 2012b; De Felice et al, 2014; Molinari et al, 2015; Mori et al,
2015). Specifically, Mori and colleagues showed a correlation of
multiple different ADC parameters with Ki-67 at a cutoff of 14%,
establishing a threshold cutoff of 1097 10 6mm2 s 1 which was
82% sensitive and 71% specific for Ki-67 proliferation. However,
they found that the high proliferation tumours had lower ADC as
opposed to our findings where low proliferation tumours had a
lower ADC value (Mori et al, 2015). On the other hand, DeFelice
and Jeh found no correlation between ADC and Ki-67 expression
(Jeh et al, 2011; De Felice et al, 2014). ADC is influenced by several
factors, including grading, with a demonstrated direct correlation
between ADC and higher tumour grade G3 (De Felice et al, 2014).
In our study, the majority of the Ki-67 negative cancers were grade
2, and this might have contributed to the lower ADC observed in
the setting of Ki-67 p14%.
There was a statistically significant correlation of a high Kepmean
with ER/PR negativity (P¼ 0.011 when compared to ER or PR þ )
and HER-2 positivity (P¼ 0.028). Enhancement characteristics
have long been of interest in differentiating subtypes and
phenotypes of breast cancer. As early as 2003, Szabo et al (2003)
evaluated breast tumours on the basis of rim enhancement,
Table 2. Receptor status and phenotype based on biopsy in 21 cases, on whole-mastectomy specimen in 16 cases, and on the
combination of whole-mastectomy specimen and biopsy
Receptor status
ERþ ER PRþ PR HER2þ HER2 Ki67þ (p14%) KI67 (414%)
Biopsy 14/21 7/21 12/21 9/21 10/21 11/21 12/21 9/21
Mastectomy 11/16 5/16 9/16 7/16 6/16 10/16 10/16 6/16
Phenotype
Luminal A Luminal B Luminal HER2 HER2 Enriched
Biopsy 3/21 8/21 3/21 7/21
Mastectomy 5/16 5/16 1/16 5/16
Biopsy plus Mastectomy 6/21 5/21 3/21 7/21
Abbreviations: ER¼oestrogen receptor expression; HER2¼human epidermal growth factor receptor 2; PR¼progesterone receptor expression; Ki67¼ antigen Ki-67.
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washout, and early maximal enhancement, demonstrating that
there was a correlation with these findings and markers of poor
prognosis. More recently, studies have corroborated our findings
of a correlation with Kep and Ki-67 proliferation (Kim et al,
2015) and ER negativity (Koo et al, 2012). Koo et al (2012) took
the evaluation one step further and showed that triple-negative
breast cancers had a higher mean Kep than luminal type breast
cancers.
There was a statistically significant correlation of a high SUVmax
with ER/PR-negative tumours (P¼ 0.005) and HER-2 positivity
(P¼ 0.046). Prior studies have gone as far as to correlate a
lower SUVmax with an improved DFS (Kadoya et al, 2013;
Aogi et al, 2015; Garcia Vicente et al, 2015) and OS (Aogi et al,
2015; Garcia Vicente et al, 2015). This suggests a link between
SUVmax and tumour biology and/or phenotype. Several prior
studies have shown a correlation with either ER or PR negativity
(Ueda et al, 2008; Groheux et al, 2011; De Cicco et al, 2013;
Kadoya et al, 2013; Miyake et al, 2014; Yoon et al, 2014) and
HER-2 enriched tumours (De Cicco et al, 2013) with an elevated
SUVmax.
Several prior studies have attempted to correlate different MR
and PET biomarkers with breast cancer phenotypes including a
high median ADC with HER-2 enriched tumours (Martincich et al,
2012), differences in ADC between multiple phenotypes (Richard
et al, 2013; Lee et al, 2016), a low SUVmax for luminal A tumours
(Miyake et al, 2014), and increased SUVmax with triple-negative
ER&/orPR+
ER &/OR PR+ ER & PR–
ER & PR–
ER &/or PR+
ER&PR–
SUVmax
Kep
ER&PR–
76 558 307 9234 10 221 11 165
ER&/orPR+
3564
20
00
30
00
40
00
50
00
60
00
70
00
80
00
90
00
10
 00
0
11
 00
0
12
 00
0
13
 00
0
5048 6492 8042 10 931 13.6
6.47 9.395 14.19 17.05 27.4
302826242220181614121086420
9.846.171.6 2.9
A B
C D
E
G H
F
Figure 1. ER and/or PR and PET/MR biomarkers. Diagram displaying the correlation between ER and/or PR expression and Kep (A). Diagram
displaying the correlation between ER and/or PR expression and SUVmax (B). ERþ and PRþ cancer: a high-resolution contrast-enhanced axial T1w
VIBE (C) is shown with the corresponding axial Kep parametric map (D) and axial PET image (E). ER and PR cancer: a perfusion subtracted MRI
(F) is shown with the corresponding parametric axial Kep parametric map (G) and axial PET image (H). The ERþ and PRþ cancer (arrow) is well
depicted after contrast (C) and shows an extremely low Kep value, as demonstrated by the black colour (D). In Kep parametric maps, low values are
displayed by dark colours (from black to dark tones of blue), meanwhile high Kep values are presented in light colours (from lighter tones of blues,
to green and then yellow). The cancer also takes up low amounts of FDG (E). The ER and PR cancer (arrow) markedly enhances after contrast
administration (F) and exhibits higher Kep values (G), as demonstrated by the light blue to green colour in the Kep parametric map. FDG uptake is
pronounced (H).
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breast cancers (Groheux et al, 2011; Yoon et al, 2014). While we
agree that evaluating for the phenotype of a malignancy is
important, rather than comparing the phenotypes by single
parameters, we propose evaluating for phenotypes based on a
multivariate algorithm. In our analysis, we compared different MR
biomarkers and SUVmax values with particular receptors, then used
a multivariate analysis to determine luminal types based on the
receptors exhibited. For example, an ADC value that correlates
with HER-2 positivity along with a mean Kep and SUVmax which
correlate with ER or PR positivity lend itself to a luminal HER-2
tumour.
In our analysis, we were in agreement with the phenotype of
breast cancer based on biopsy in 16/21 (67%) cases. However, after
cross validation only 8/21 phenotypes (38%) were predicted, and
this was not statistically significant (P¼ 0.22). However, based on
excised specimens in those with residual cancer plus biopsy for
those with complete response, we correctly predicted the
phenotype in 13 of 21 patients (62%), and these predictions
Her2+
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Her2– Her2–
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Her2–
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0
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I
Figure 2. Her2 and PET/MR biomarkers. Diagram demonstrating correlation between Her2 expression and Kep (A); diagram showing correlation
between Her2 expression and ADC (B); diagram displaying correlation between Her2 expression and SUVmax (C). Her2þ cancer (D–F). A Kep
parametric map (D) is shown with a corresponding ADC map (E) and axial PET (F). The Her2þ cancer (arrow) demonstrates high Kep values
(light blue) (D), low ADC values (dark grey) (E), and high FDG uptake (F). Her2 cancer (G–I). A Kep parametric map (G) is shown with a
corresponding ADC map (H) and axial PET (I). Her2 cancer displays low Kep values (dark blue) (G), high ADC values (light gray) (F), and low
FDG uptake (I).
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retained statistical significance after cross-validation predicting 10
out of 21 cases (48%; P¼ 0.004). Although these initial results are
encouraging, the prediction rate is still low and they cannot
be translated into clinical practice. The incapability to be correct
in predicting the remaining cases could be potentially explained
by the heterogeneity of the primary breast cancer and by the
necessity to rely on biopsy for the 5 cases that experienced
complete response after neoadjuvant chemotherapy. In these 5
cases, we had to use the IHC performed on the small biopsied
portion of the cancer for the analysis. PET/MR, assessing the entire
tumour, can potentially provide a more comprehensive assessment
of its biology compared to biopsy, which is limited to a small area
of the cancer, not always representative of the entire neoplastic
biology.
A significant limitation to our study is the small number of
cases. Therefore, our data should be considered as a preliminary
investigation. A larger sample size would increase our power for
identifying more useful MR and PET biomarkers. Other studies
showed a statistically significant correlation between Ki-67 level
and SUVmax (Buck et al, 2002; De Cicco et al, 2013; Yue et al,
2015); the lack of correlation in our study might be related to
differences in population and/or sample size. Additional biomar-
kers as supported by a larger study may lead to improved
phenotypic identification by imaging. With data from more
patients we could build a more reliable and accurate algorithm
that could be validated prospectively.
Our findings also relied on regions of interest (ROIs), which
included the whole tumour rather than spot ROIs. Spot ROIs may
better account for tumour heterogeneity, especially in the case of
large tumours. Although PET/MR is capable of providing such
spot ROIs, they might need to be checked against the exact same
corresponding area within the sliced tumour.
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Figure 3. Ki67 and PET/MR biomarkers. Diagram displaying correlation between expression of Ki67 and ADC mean (A). Ki67 cancer (B and C).
Axial high-resolution contrast-enhanced MRI (B) is shown with a corresponding ADC map (C). The Ki67 cancer (arrow) demonstrates low values
on the ADC map (C). Ki67þ cancer (D and E). An axial high-resolution contrast-enhanced MRI (D) is shown with a corresponding ADC map (E). The
Ki67þ cancer (arrow) exhibits higher ADC values (E).
Table 3. Schematic of PET/MR biomarkers according to receptor status and grading
ER/PR ER or
PRþ
P-
value
HER2 HER2þ P-value Ki67p14% Ki67414% P-
value
G2 G3 P-value
Kepmean
(min 1)
9234±1320 6492±2359 0.011 8599±2122 6322±2241 0.028 6974±2652 7622±2380 0.577 6638±2392 8944±1765 0.036
ADCmean
(10 6mm2/s)
1275±130 1096±288 0.139 1303±121 1022±280 0.009 964±242
904±240*
1252±214
1216±230*
0.025 1099±290 1268±131 0.633
SUVmax 14.19±7.17 6.18±4.34 0.005 11.79±7.65 6.17±4.02 0.046 5.9±4.97 10.31±6.88 0.149 6.83±4.73 12.89±8.08 0.042
Abbreviations: ADC¼ apparent diffusion coefficient; ER¼oestrogen receptor expression; HER2¼human epidermal growth factor receptor 2; MR¼magnetic resonance; PET¼positron
emission tomography; PR¼progesterone receptor expression; Ki67¼ antigen Ki-67. ER, PR, and HER2 expression was concordant on whole-mastectomy assessment and biopsy. Different
expression of Ki67 was encountered between whole-mastectomy specimen and biopsy, therefore the latter has been indicated by *. Statistically significant results are in bold.
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In a study by Arponen and colleagues, they demonstrated that
by placing ROIs in the area of the tumour with the lowest ADC
they could show a significant correlation with low ADC and
axillary lymph node metastases, lymphovascular invasion, and high
tumour grade. This was in addition to the correlation that was seen
in both whole-tumour ROIs and spot ROIs with low ADC that
included PR positivity and stage (Arponen et al, 2015). PET/MR
derived colour-coded biomarker maps are amenable to a section-
by-section analysis to highlight the differences in phenotype
expression in different areas of each section, pointing out the most
aggressive ones that need to be selectively biopsied. The targeting
of biopsies for the areas of the primary breast cancer with more
concerning features by MR biomarkers may be a future direction.
A comparison between random and targeted biopsies could be
evaluated for clinically significant heterogeneity. This likely
explains the differences in Ki67 expression between biopsy and
surgical pathology that occurred in 3 cases. However, a different
response to therapy of different neoplastic clones cannot be
completely ruled out as an explanation for this discordance.
Evaluation of untreated cancers might overcome this possible
limitation. However as per current NCCN guidelines, neoadjuvant
chemotherapy is administered to stage IIA, IIB and III cancers that
fulfil criteria for breast-conserving surgery except for tumour size
(National Comprehensive Cancer Network, 2016).
This preliminary study does have additional limitations. We
used FDG since it is the most commonly clinically available
radiopharmaceutical and to make our results potentially verifiable
by other groups. Receptor-specific radiopharmaceuticals were not
used because they are not widely available. This would have
potentially rendered our study irreproducible, more expensive (our
study was self-funded), and moreover a single receptor-specific
radiopharmaceutical might have highlighted only one feature of
the receptor expression profile of the cancers. However, we are
aware that other radiopharmaceuticals showed potential to
characterise breast cancer better that FDG (van de Wiele et al,
2002; Van Den Bossche et al, 2006; Siwowska and Muller, 2015;
Accardo et al, 2016; Park et al, 2016).
Moreover, we acquired PET/MR 85±24min after FDG
injection, instead of the usual incubation period of 60min. Our
longer incubation time is explained by the legal obligation and IRB
requirements to perform a standard of care PET-CT at 60min after
FDG injection, before acquiring a PET-MR study. However, it is
unlikely that this influenced the FDG values we measured. In fact,
the PET-MR reconstruction software, approved for clinical use
worldwide, automatically corrects for the delay between the time of
FDG injection and the time of PET data acquisition for each bed
position. Moreover, several studies have demonstrated comparable
SUV values between PET-CT and subsequently acquired PET-MR
(Pace et al, 2014; Atkinson et al, 2016; Pujara et al, 2016).
The main technical limitation was the use of a PET/MR
compatible body coil for PET attenuation correction. In
subsequently acquired patients, including follow-ups on this
same cohort, we used a dedicated PET/MR compatible breast coil
that was not available at the start of the project. However, to
ensure consistency, we preferred not to combine patients
acquired with different coils. For a preliminary feasibility study,
we believe that the findings of properly identifying the breast
cancer phenotype in 62–67% of cases is promising regarding the
potential of CE-FDG PET/MR to non-invasively assess whole-
tumour phenotypes.
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